As new drugs become available for the treatment of an expanding list of health conditions, drug developers have increasingly pursued packaging and delivery options that simplify the administration process and increase the efficiency and reliability with which the drug can be introduced into the patient. For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug marketers.
As the administration of injectables moves increasingly from practitioner offices and healthcare facilities to patient homes, decisions regarding as-supplied packaging that were once considered boilerplate have moved to the early stages of the development process. A wide spectrum of device attributes, including form factor, device-patient interaction, security and safety, dosing, activation, off-device communication, and drug formulation factors have been incorporated into drug injection devices. Over time, these initiatives will come to be expected by patients in injectable drugs.
What You Will Learn
- What on-body subcutaneous systems are currently marketed or in development, who are the suppliers, and what are the device specifics?
- What are the therapeutic markets being targeted by on-body subcutaneous injection systems?
- What are the essential design factors, material selection issues, technologies and market development issues for on-body subcutaneous injection systems?
- What are the major factors that will drive on-body subcutaneous injection systems demand?
- How are on-body subcutaneous injection systems currently aligned with various drug classes and therapeutic markets?
- What is the addressable market for on-body subcutaneous injection systems?
- What is the expected impact of on-body subcutaneous injection systems on drug delivery markets?
- Who are the significant players in this segment? What are their strategies? Who are their alliance partners?
Report Value Matrix - Who Should Read this Report
- Managed Care Managers
- Management Consultants
- Financial Analysts
- Pharma Product Managers
- Device Suppliers
- Biotech Managers
- Product Developers
- Drug Marketers & Strategists
- Clinical Component Suppliers
- CMOs, CSOs Managers
- Drug Distributors
- Pharma Regulators
1. Executive Summary
2. Subcutaneous Injectable Therapeutics Landscape
- Therapeutic Drug Development
- Drug Delivery Device Evolution
- On-body SC System Enabling Technologies
- Device-Drug Developer Collaborations
3. Device Design Factors
- Primary Container
- Injection Methodology
- Electronics and System Features
- Patient Interface
4. On-Body Subcutaneous Device Classes
- Electronic Disposable
- Electronic Semi-disposable
- E3D Patch Pump
- OmniPod (non-insulin version)
- SensePatch SD
- Unbranded (Medicom)
- Mechanical Disposable
- Enable Injector
- Lapas AR
- Captive Devices
- Product Specific Devices
- Neulasta On-body Injector
5. Near-term Product Analysis and Market Data
- Blood Factors
- Monoclonal Antibodies
6. Market Factors
- Regulatory Factors
- Patient Training and Ease of Use
- Adherence and Adverse Reactions
7. Company Profiles
- Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.
- Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.
- Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.